目的：通过检测阿托伐他汀在慢阻肺患者不同治疗阶段血清TGF-β1水平的变化情况,探讨慢阻肺气道重构的机制及阿托伐他汀在慢阻肺气道重构发病过程中所发挥的保护性作用。方法80例慢阻肺患者分为急性加重期40例和稳定期40例,在常规治疗的基础上均给予阿托伐他汀片20 mg/d,睡前一次口服,分别于治疗前、治疗2、4、6个月后清晨空腹抽取肘静脉血检测血清TGF-β1水平。结果治疗前TGF-β1水平急性加重期患者明显高于稳定期患者(P<0．01)。两组阿托伐他汀治疗2、4、6个月后TGF-β1水平均明显降低,且随治疗时间的延长TGF-β1水平下降更明显,与治疗前比较差异均有统计学意义(均P<0．01)。结论 TGF-β1可能参与了慢阻肺的气道重构,阿托伐他汀可通过降低慢阻肺患者血清TGF-β1表达,抑制气道平滑肌细胞增殖和细胞外基质沉积,减缓气道重构。%Objective To investigate the protective effect of atorvastatin in the treatment of patients with chronic obstruct pulmonary disease ( COPD) . Methods 80 cases of COPD were divided into the acute exacerbation group (40 cases) and the stable group (40 cases). All the patients were given atorvastatin tables orally 20mg once a day on the basis of routine treatment. Morning fasting blood was taken from cubital vein before and 2, 4 and 6 months after the treatment. The serum level of TGF-β1 was detected. Results Before the treatment, the serum level of TGF-β1 was higher in the acute exacerbation group than in the stable group ( P<0. 01 ) . After the treatment, the level of TGF-β1 decreased obviously in both groups ( all P<0. 01 ) . Conclusion TGF-β1 may be involved in the airway remodeling of COPD, and atorvastatin can reduce the expression of serum TGF-β1.
展开▼
